Treatment of Secondary Polycythemia in Chuvash Polycythaemia with Homozygous VHL Gene Mutation

Clinical Scenario

This protocol addresses secondary polycythemia in patients with Chuvash polycythaemia — a hereditary condition characterised by a homozygous mutation in the VHL gene. The elevated haematocrit in these patients reflects the direct physiological consequence of the underlying mutation, which distinguishes this form from other secondary polycythaemias and shapes how treatment decisions are made.

Why This Population Requires Special Consideration

In Chuvash polycythaemia, the homozygous VHL gene mutation drives a specific disease biology. Increased thrombotic complications have been reported in affected individuals, making the risk-benefit assessment of haematocrit-lowering interventions more complex than in the general secondary polycythaemia population.

Treatment Approach

Management in this setting involves antiplatelet therapy as a core consideration. Decisions about haematocrit reduction carry particular nuance here: the raised haematocrit reflects the physiological state imposed by the VHL mutation, and interventions aimed at reducing it must be weighed carefully in this specific context.

The complete structured regimen — agents, indications, sequencing, and clinical decision criteria — is available in the full protocol.